argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
[email protected]
Investors:
Alexandra Roy
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedInsider and Carahsoft Co-Host Carahsoft’s Fourth Annual 5G Summit in Reston, Va., on Aug. 25, 2026
- Revolution Foods Acquires Ardella’s, 50-Year-Old Family Company Behind Student-Favorite Pizzas and Burritos
- Two Days After Releasing HiPHI, Noitom Robotics and Collaborators Demonstrate Humanoid Robots Playing Professional-Style Tennis
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share